Prascend 1 mg 60ct

Prascend 1 mg 60ct
Prascend 1 mg 60ctPrascend 1 mg 60ct
SALE $124.99
Regular Price:$149.99
Item#:prasc60
Qty:
PRASCEND (pergolide mesylate) is the first and only medicine available in the US that is fully approved by the FDA to treat pituitary pars intermedia dysfunction (more commonly called PPID or equine Cushing's disease) in horses. PPID affects 1 in 7 horses and ponies over 15 years of age, and may not show any signs until disease reaches an advance stage.

For the control of clinical signs associated with Pituitary Pars Intermedia Dysfunction (Equine Cushing’s Disease) in horses. Prascend (pergolide mesylate) Tablets are available in 1 mg strength - packaged 10 tablets per blister and 60 or 160 tablets per carton.

Storage: Store at or below 25°C (77°F).

Precautions: Treatment with Prascend may cause loss of appetite, lethargy, diarrhea, and other behavioral changes. The use of Prascend in breeding, pregnant, or lactating horses has not been evaluated. The pharmacologic action of pergolide mesylate suggests that it may interfere with reproductive functions such as lactation.

Prascend is approximately 90% associated with plasma proteins. Use caution if administering Prascend with other drugs that affect protein binding. Dopamine antagonists, such as neuroleptics (phenothiazines, domperidone) or metoclopramide, ordinarily should not be administered concurrently with Prascend (a dopamine agonist) since these agents may diminish the effectiveness of Prascend.



Administer orally at a starting dose of 2 mcg/kg once daily. Dosage may be adjusted to effect, not to exceed 4 mcg/kg daily. May cause eye irritation, an irritating smell, or headache when Prascend Tablets are split or crushed.

Dosage Chart
Dosage
Body weight 2 mcg/kg 4 mcg/kg
136 - 340 kg
(300 - 749 lb)
0.5 tablet 1 tablet
341 - 568 kg
(750 - 1,249 lb)
1 tablet 2 tablets
569 - 795 kg
(1,250 - 1,749 lb)
1.5 tablets 3 tablets
796 - 1,022 kg
(1,750 - 2,249 lb)
2 tablets 4 tablets